Published in J Thorac Oncol on April 15, 2016
Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody. Invest New Drugs (2016) 0.87
Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci (2017) 0.82
Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy. Ther Adv Med Oncol (2017) 0.81
Recent Advances in Immunotherapy in Metastatic NSCLC. Front Oncol (2016) 0.79
Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer. Front Oncol (2017) 0.79
Targeting ALK: Precision Medicine Takes on Drug Resistance. Cancer Discov (2017) 0.78
Adding checkpoint inhibitors to tyrosine kinase inhibitors targeting EGFR/ALK in non-small cell lung cancer: a new therapeutic strategy. Invest New Drugs (2016) 0.77
Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line. Front Med (Lausanne) (2017) 0.77
Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors. J Biomed Sci (2016) 0.77
Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer. Front Oncol (2017) 0.77
Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care. Radiographics (2017) 0.75
Osimertinib-induced interstitial lung disease in a patient with non-small cell lung cancer pretreated with nivolumab: A case report. Mol Clin Oncol (2017) 0.75
Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer. Target Oncol (2017) 0.75
Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found…. ESMO Open (2017) 0.75
LBA2_PR: Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results. J Thorac Oncol (2016) 1.13
LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts. J Thorac Oncol (2016) 0.86
134O_PR: Plasma ctDNA analysis for detection of EGFR T790M mutation in patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (aNSCLC). J Thorac Oncol (2016) 0.78
135O_PR: Plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLC. J Thorac Oncol (2016) 0.78
151P: Outcomes of research biopsies in clinical trials of EGFR mutation-positive NSCLC patients pretreated with EGFR-TKIs. J Thorac Oncol (2016) 0.76